Synovis Life Technologies Q3 results trump estimates
Synovis Life Technologies, Inc. (Nasdaq:SYNO) this morning reported third fiscal quarter results that bested the consensus on Wall Street as growth continued in each of the medical device company’s product areas.
Gross margin rose to 69% from 65% in the third quarter last year, as the company realized higher-margin sales of its Veritas and Peri-Strips products. Improved labor and material utilization coupled with lower obsolescence expense and increased average net sales prices also converged to boost margins.
Shares gained 6%, or $1.43, to $24 in pre-market trading. For detailed price information and news stories on Synovis Life Technologies, click SYNO.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
